A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AUPH SEC filings page.
Aurinia Pharmaceuticals Inc (AUPH) reported $321.7M in revenue over the twelve months to Sep 30, 2026, up 21.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 marks a shift from development-stage losses to operating profitability, but net income was amplified by a large tax benefit.
The earnings breakthrough is stronger at the operating line than at the bottom line: operating income reached$104.9M , while a reported tax benefit of$173.0M pushed net income higher. Cash conversion was incomplete: operating cash flow was$135.7M , equal to only47.2% of net income, so reported profit included a substantial tax contribution beyond operating earnings.
Revenue increased
Assets grew
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aurinia Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Aurinia Pharmaceuticals Inc scores 47/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Aurinia Pharmaceuticals Inc scores 87/100 on it among other operating companies.
Aurinia Pharmaceuticals Inc carried $0.29 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, Aurinia Pharmaceuticals Inc is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 72/100 among other operating companies measured the same way.
Aurinia Pharmaceuticals Inc held $5.25 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 5.25. Liquidity ranks operating companies on that ratio, and Aurinia Pharmaceuticals Inc scores 92/100 among other operating companies.
Not available for Aurinia Pharmaceuticals Inc, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Aurinia Pharmaceuticals Inc scores 38/100 on it among other operating companies.
Aurinia Pharmaceuticals Inc scores 7.21, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $2.0B against total liabilities of $170.3M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aurinia Pharmaceuticals Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Aurinia Pharmaceuticals Inc generates $0.47 in operating cash flow ($135.7M OCF vs $287.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Aurinia Pharmaceuticals Inc earns $24.23 in operating income for every $1 of interest expense ($104.9M vs $4.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Aurinia Pharmaceuticals Inc generated $83.7M in revenue in Q3 2026. This represents an increase of 13.9% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.
Aurinia Pharmaceuticals Inc's EBITDA was $40.2M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.2% from the same quarter a year earlier. Against the prior quarter it is down 21.4%.
Aurinia Pharmaceuticals Inc reported $31.7M in net income in Q3 2026. This represents an increase of 0.5% from the same quarter a year earlier. Against the prior quarter it is down 15.3%.
Aurinia Pharmaceuticals Inc earned $0.23 per diluted share (EPS) in Q3 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 17.9%.
Cash & Balance Sheet
Aurinia Pharmaceuticals Inc held $45.8M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Aurinia Pharmaceuticals Inc's gross margin was 90.1% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.0 percentage points.
Aurinia Pharmaceuticals Inc's operating margin was 42.3% in Q3 2026, reflecting core business profitability. This is up 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 13.4 percentage points.
Aurinia Pharmaceuticals Inc's net profit margin was 37.9% in Q3 2026, showing the share of revenue converted to profit. This is down 5.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.1 percentage points.
Aurinia Pharmaceuticals Inc's quarterly ROE was 4.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.
Capital Allocation
Aurinia Pharmaceuticals Inc invested $16.6M in research and development in Q3 2026. This represents an increase of 97.0% from the same quarter a year earlier. Against the prior quarter it is up 27.3%.
Aurinia Pharmaceuticals Inc repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q3 2026.
AUPH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.7M+13.9% | $83.2M+18.9% | $77.7M+24.4% | $77.1M+28.8% | $73.5M+8.4% | $70.0M+22.4% | $62.5M+24.2% | $59.9M+32.8% |
| Cost of Revenue | $8.3M+1.6% | $6.6M-7.9% | $6.5M-24.1% | N/A | $8.2M+35.5% | $7.1M-20.1% | $8.6M+10.6% | N/A |
| Gross Profit | $75.4M+15.5% | $76.7M+21.9% | $71.2M+32.1% | N/A | $65.3M+5.8% | $62.9M+30.3% | $53.9M+26.7% | N/A |
| R&D Expenses | $16.6M+97.0% | $13.1M+75.6% | $7.5M+30.1% | N/A | $8.4M+176.8% | $7.4M+82.2% | $5.7M+3.5% | N/A |
| SG&A Expenses | $24.7M-5.7% | $23.5M-9.6% | $22.0M+8.3% | N/A | $26.2M-38.2% | $26.0M-42.1% | $20.3M-57.4% | N/A |
| Operating Income | $35.4M+18.9% | $46.3M+130.7% | $41.4M+89.6% | $33.2Mn/m | $29.7M+153.2% | $20.1Mn/m | $21.8Mn/m | -$1.7Mn/m |
| EBITDA | $40.2M+16.2% | $51.2M+105.1% | $46.2M+73.2% | $38.1M+1093.3% | $34.6M+108.0% | $24.9M+649.2% | $26.7Mn/m | $3.2Mn/m |
| Interest Expense | $867K-21.1% | $948K-15.1% | $1.0M-5.2% | N/A | $1.1M-9.0% | $1.1M-6.8% | $1.1M-16.8% | N/A |
| Income Tax | $7.0M+1606.1% | $11.4M+1668.6% | $9.6M+852.2% | N/A | $411K-10.1% | $643K-14.9% | $1.0M+36.0% | N/A |
| Net Income | $31.7M+0.5% | $37.4M+73.9% | $34.4M+47.2% | $210.8M+14651.2% | $31.6M+119.9% | $21.5M+2879.6% | $23.3Mn/m | $1.4Mn/m |
| EPS (Basic) | $0.240.0% | $0.29+81.2% | $0.26+52.9% | $1.60+15900.0% | $0.24+140.0% | $0.16+1500.0% | $0.17n/m | $0.01n/m |
| EPS (Diluted) | $0.230.0% | $0.28+75.0% | $0.25+56.3% | $1.53+15200.0% | $0.23+130.0% | $0.16+1500.0% | $0.16n/m | $0.01n/m |
| Diluted Shares (Avg) | 135M-0.6% | 134M-2.9% | 138M-3.9% | N/A | 136M-6.6% | 138M-4.6% | 143M-0.6% | N/A |
AUPH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $825.7M+56.5% | $792.3M+57.6% | $724.0M+43.4% | $751.6M+36.5% | $527.5M-4.0% | $502.6M-4.0% | $504.9M-2.3% | $550.6M+0.5% |
| Current Assets | $587.9M+34.0% | $541.3M+32.4% | $480.2M+18.4% | $492.0M+10.2% | $438.7M-0.4% | $409.0M-0.2% | $405.8M+1.9% | $446.6M+5.1% |
| Cash & Equivalents | $45.8M-37.2% | $179.7M+239.7% | $40.7M-38.4% | $80.2M-3.9% | $72.9M+99.0% | $52.9M+59.1% | $66.1M+3.4% | $83.4M+71.1% |
| Short-Term Investments | $440.7M+58.2% | $263.3M+0.4% | $337.8M+37.0% | $317.8M+15.5% | $278.6M-10.6% | $262.1M-11.8% | $246.5M-3.5% | $275.0M-8.8% |
| Inventory | $43.7M-2.4% | $45.2M-2.9% | $46.4M+0.5% | $45.7M+16.5% | $44.8M+15.7% | $46.5M+19.7% | $46.2M+16.2% | $39.2M-1.2% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $168.2M+4.0% | $177.4M+6.1% | $156.4M+1.1% | $170.3M-1.7% | $161.8M+0.2% | $167.3M+5.3% | $154.7M-1.6% | $173.2M+1.8% |
| Current Liabilities | $96.0M+26.0% | $99.9M+27.6% | $86.6M+26.5% | $93.7M-4.1% | $76.2M-3.0% | $78.3M+1.8% | $68.4M-3.7% | $97.8M+26.7% |
| Non-Current Liabilities | $72.2M-15.6% | $77.5M-12.9% | $69.8M-19.1% | $76.5M+1.5% | $85.5M+3.4% | $89.0M+8.5% | $86.3M+0.2% | $75.4M-18.9% |
| Total Equity | $657.5M+79.8% | $614.9M+83.4% | $567.6M+62.1% | $581.3M+54.0% | $365.8M-5.7% | $335.3M-8.0% | $350.2M-2.6% | $377.5M-0.1% |
| Retained Earnings | -$545.9Mn/m | -$577.6Mn/m | -$615.0Mn/m | -$649.4Mn/m | -$860.2Mn/m | -$891.7Mn/m | -$913.2Mn/m | -$936.6Mn/m |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
AUPH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $46.4M+4.3% | $52.6M+18.8% | $32.6M+2404.6% | $45.7M+51.7% | $44.4M+161.0% | $44.2M+179.2% | $1.3Mn/m | $30.1M+110.4% |
| Depreciation & Amortization | $4.8M-0.5% | $4.8M-0.6% | $4.8M-0.8% | $4.9M0.0% | $4.9M-0.6% | $4.9M+0.4% | $4.9M+0.2% | $4.9M |
| Stock-Based Compensation | $6.1M+3.5% | $2.8M-47.8% | -$866Kn/m | N/A | $5.9M-28.9% | $5.4M-36.6% | -$3.4M-159.4% | N/A |
| Investing Cash Flow | -$175.7Mn/m | $81.4Mn/m | -$18.1M-158.3% | -$36.8M-193.7% | -$13.8Mn/m | -$13.3Mn/m | $31.0M-37.0% | $39.2Mn/m |
| Financing Cash Flow | -$4.3Mn/m | $4.8Mn/m | -$53.7Mn/m | -$1.9Mn/m | -$10.5Mn/m | -$44.4Mn/m | -$49.3Mn/m | -$23.0Mn/m |
| Share Buybacks | $0-100.0% | $38.7M-9.0% | $36.2M-22.9% | $0-100.0% | $8.7Mn/m | $42.6M+593.9% | $46.9M+281.4% | $21.8Mn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
AUPH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.1%+1.2pp | 92.1%+2.3pp | 91.6%+5.4pp | N/A | 88.9%-2.2pp | 89.8%+5.4pp | 86.3%+1.7pp | N/A |
| Operating Margin | 42.3%+1.8pp | 55.7%+27.0pp | 53.3%+18.3pp | 43.1%+45.9pp | 40.5%+23.2pp | 28.7%+31.3pp | 35.0%+61.3pp | -2.8%+63.0pp |
| Net Margin | 37.9%-5.1pp | 45.0%+14.2pp | 44.2%+6.8pp | 273.3% | 43.0%+21.8pp | 30.7%+29.5pp | 37.4%+58.7pp | 2.4%+62.0pp |
| Return on Equity | 4.8%-3.8pp | 6.1%-0.3pp | 6.0%-0.6pp | 36.3%+35.9pp | 8.6%+4.9pp | 6.4%+6.2pp | 6.7%+9.7pp | 0.4%+7.5pp |
| Return on Assets | 3.8%-2.1pp | 4.7%+0.4pp | 4.8%+0.1pp | 28.1%+27.8pp | 6.0%+3.4pp | 4.3%+4.1pp | 4.6%+6.7pp | 0.3%+5.2pp |
| Current Ratio | 6.12+0.4x | 5.42+0.2x | 5.55-0.4x | 5.25+0.7x | 5.76+0.2x | 5.23-0.1x | 5.93+0.3x | 4.57-0.9x |
| Liabilities-to-Equity | 0.26-0.2x | 0.29-0.2x | 0.28-0.2x | 0.29-0.2x | 0.440.0x | 0.50+0.1x | 0.440.0x | 0.460.0x |
| Asset Turnover | 0.100.0x | 0.110.0x | 0.110.0x | 0.100.0x | 0.140.0x | 0.140.0x | 0.120.0x | 0.110.0x |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc AUPH | FY2025 | $283.1M | $287.2M | N/A | $2.0B | 67/100 |
| Vera Therapeutics, Inc. VERA | FY2025 | N/A | -$299.6M | N/A | $1.8B | — |
| Septerna, Inc. SEPN | FY2025 | $46.0M | -$48.9M | N/A | $1.8B | 46/100 |
| Immunome, Inc. IMNM | FY2025 | $6.9M | -$212.4M | N/A | $1.9B | 50/100 |
| Biohaven Ltd. BHVN | FY2025 | N/A | -$738.8M | N/A | $1.9B | — |
| Celldex Therapeutics, Inc CLDX | FY2025 | $1.5M | -$258.8M | N/A | $2.2B | 56/100 |
Where Aurinia Pharmaceuticals Inc Ranks
Frequently Asked Questions
Aurinia Pharmaceuticals Inc (AUPH) reported $283.1M in total revenue for fiscal year 2025. This represents a 20.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Aurinia Pharmaceuticals Inc (AUPH) revenue grew by 20.4% year-over-year, from $235.1M to $283.1M in fiscal year 2025.
Yes, Aurinia Pharmaceuticals Inc (AUPH) reported a net income of $314.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $287.2M.
Aurinia Pharmaceuticals Inc (AUPH) had EBITDA of $124.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Aurinia Pharmaceuticals Inc (AUPH) had a gross margin of 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Aurinia Pharmaceuticals Inc (AUPH) had an operating margin of 37.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Aurinia Pharmaceuticals Inc (AUPH) has a return on equity of 49.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Aurinia Pharmaceuticals Inc (AUPH) generated $135.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Aurinia Pharmaceuticals Inc (AUPH) had $751.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Aurinia Pharmaceuticals Inc (AUPH) invested $32.5M in research and development during fiscal year 2025.
Aurinia Pharmaceuticals Inc (AUPH) had a current ratio of 5.25 as of fiscal year 2025, which is generally considered healthy.
Aurinia Pharmaceuticals Inc (AUPH) had a liabilities-to-equity ratio of 0.29 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Aurinia Pharmaceuticals Inc (AUPH) had a return on assets of 38.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Aurinia Pharmaceuticals Inc (AUPH) trades at 6.3x earnings, its market capitalization divided by $314.3M net income, trailing 12 months to September 30, 2026. The market capitalization is $2.0B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Aurinia Pharmaceuticals Inc (AUPH) trades at 6.1x sales, its market capitalization divided by $321.7M revenue, trailing 12 months to September 30, 2026. The market capitalization is $2.0B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Aurinia Pharmaceuticals Inc (AUPH) has an Altman Z-Score of 7.21, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Aurinia Pharmaceuticals Inc (AUPH) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Aurinia Pharmaceuticals Inc (AUPH) has an earnings quality ratio of 0.47x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Aurinia Pharmaceuticals Inc (AUPH) has an interest coverage ratio of 24.23x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Aurinia Pharmaceuticals Inc (AUPH) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Aurinia Pharmaceuticals Inc it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.